Amazing people reunited in Buenos Aires for one project in common. Great time, thank you guys! Sarcoma European LatinAmerican Network (SELNET) Dr. Tomás Soulé Jon Trent, MD, PhD Dra Maria Lucila Gonzalez Donna Celso Mello Nathalie Emmanuel #sarcoma #oncology #meeting #research

Celso Mello on #desmoid in pregnancy #SBOC2023 SOS DESMOIDE

#desmoid tumor pathways reported by Celso Mello #SBOC2023 Veridiana Pires De Camargo Dario Callegaro Philippos Apolinario Costa, MD SOS DESMOIDE

“First do no harm” rationale for active surveillance of #desmoid tumor patients by Dario Callegaro #SBOC2023 Veridiana Pires De Camargo Celso Mello Philippos Apolinario Costa, MD SOS DESMOIDE

Celso Mello discussing management of #desmoid tumor during #pregnancy Important role of #patient associations in 🇧🇷 to guide and support #desmoideBrasil patients #SBOC2023 Desmoid Foundation ONLUS - Italia Desmoid Tumor Research Foundation Jon Trent, MD, PhD

Thrilled to have welcomed Jon Trent, MD, PhD and Dario Callegaro to Rio for the #sboc2023 congress – an enriching experience with insightful discussions in #sarcoma and #gist in the past 3 days. 🧬🔬🧪

Nosso conselheiro médico da #DesmoideBrasil Dr Celso Mello falando sobre DESMOIDE e gravidez na #SBOC2023 💪🏽👏

It was a great discussion and we are looking forward for the Consensus paper in which you could participate representing the Brazilian patients.

Avapritinib ha obtenido (¡al fin!) la aprobación en España para pacientes con #GIST con la mutación #PDGFRA D842V 👉El estudio NAVIGATOR demostró una actividad sin precedentes en estos pacientes para los que no existía ningún tratamiento efectivo 🔗thelancet.com/journals/lanon…

This is an exciting day for desmoid tumor patients! The first-ever medical therapy approved for desmoid tumors.

Fantastic night UK Prime Minister for the Sarcoma UK Shining Star Awards. Grateful to have won "Research of the Year" award on behalf of our wonderful The ICR The Royal Marsden NHS Foundation Trust Team. Thanks to everyone who voted for us & Larry the Cat for gracing us with his presence! 🎉🥳🌟

Always very stimulating the meetings to discuss new projects to support our patient with #desmoidtumor. Quiró, #brunadabiv, Livia, Philippos Apolinario Costa, MD #DTRFoundation #desmoidtumor #sarcoma #sarcomaadvocacy

Join me, The Life Raft Group, & Cogent Biosciences at an educational webinar for the #GIST Patient & Caregiver Community. I will be presenting an overview of the Peak Clinical Trial (NCT05208047). #sarcoma Dec 13, 2023 @ 7pm ET Register using the link here: events.bizzabo.com/GIST_ClinicalT…

Excelente evento hoje Genômica em #oncologia . #hereditarytumors #multigenepanel #Genomics Felipe D'Almeida Giovana Torrezan Celso Mello Illumina A.C.Camargo Cancer Center

The impressive efficacy of TKI and immunotherapy presented by Javier Martin Broto including axitinib + pembrolizumab and sunitinib+nivolumab combinations. Exciting time for #sarcoma #immunotherapy GEIS Hellenic Group of Sarcomas and rare tumors

Yesterday, Dr. Medina and Dra. Kinker were awarded the Veja Saúde/Oncoclínicas best work in Genomics and Precision Medicine of the year for the work on the role of TLS in pancreatic cancer immune response. Honored to be part of this endeavour and work with such brilliant people.

What happens when pts with MSI-H/dMMR met CRC stop immunotherapy even after prolonged benefit? Our 🌟 BCM Hematology-Oncology Fellowship Dr Kristen Simmons 🌟 reported that cancer never worsens in >85% cases once off treatment. AACR Cancer Research Communications MD Anderson Cancer Center #endcancer

"Exciting findings from the OS2006. CtDNA emerges as promising prognostic factor. PRONOS prediction tool shows good performance in individual risk estimation. #Osteosarcoma #sarcoma Sarcoma European LatinAmerican Network (SELNET) A.C.Camargo Cancer Center Giovana Torrezan 🧬🩸💉🦴annalsofoncology.org/article/S0923-…

Presence of ctDNA Does Not Predict Benefit of Adjuvant Chemotherapy in Stage II Colon Cancer Van Morris, MD MD Anderson Cancer Center @asco #GI24 #crcsm onclive.com/view/presence-…

Abstracts are out for #ESMOSarcomaAndRareCancers2024! Check out our poster on “Assessment of rare cancers’ and sarcoma policy in National Cancer Control Plans (NCCPs) from South American Countries: a report from the LACOG Sarcoma Group”. Grateful for receiving an ESMO - Eur. Oncology